Over the past decade, we’ve observed a rise in patients’ power and engagement regarding their own care.
The concept of Evidence-based medicine has also emerged with the goal of delivering the right care at the right time to the right patient. One of the core concepts of Evidence-based medicine is patient preference.
Industry, regulators, HTA bodies and players are showing more and more interest in the use of patient preference studies. The goal is to help incorporate the patient perspective into clinical drug development, care management, and healthcare decision-making.
In this context, most of the pharmaceutical companies want to be patient-centric, but it’s not always clear how and when to include patient perspective into the product development cycle.
The following interview with Lise Radoszycki, COO at Carenity and Global Head of Data Science at EvidentIQ, will give us an overview of preference study methodologies focusing on Discrete Choice Experiments (DCE), and will share light on how to optimize DCE design to improve the quality on patient studies.
Read the interview conducted by Gilda Teissier, Executive Marketing Director at EvidentIQ here 🎤👇
For more information about EvidentIQ’s and Carenity’s solutions click here.